Cannabis « AGORACOM Small-cap Investor Relations Blog

Posts Tagged ‘Cannabis’

CBD Demand Could Drive 2020 Sales of $2 Billion SPONSOR: Thoughtful Brands International $TBI.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca $NOVA.ca

Posted by AGORACOM at 10:09 AM on Thursday, November 12th, 2020

SPONSOR: Thoughtful Brands is an established natural health products company focused in the CBD and psychedelic medicine sectors. Through their powerful eCommerce business, Thoughtful is a leading direct-to-consumer provider of a wide range of natural health products throughout the United States and Europe

CBD beauty products are projected to reach $191 million in 2020, with estimated 7% growth to $507 million by 2025
Likewise, the hemp-CBD pet products market, estimated at $191 million in sales this year, is projected to grow 7% in five years to $506 million. Like food, however, growth of the pet-products sector is highly dependent on regulatory clarity

Consumers are already going gangbusters for CBD in every formulation imaginable.

But the current use rate for hemp-CBD products isn’t even close to what it could be when the industry sees federal regulation, which would open up mainstream manufacturing and retail markets even further.

For 2019, total sales of hemp-derived CBD consumer products in the U.S. were roughly $1.2 billion, according to Nielsen Global Connect, a division of Nielsen that focuses on data for hemp-derived CBD manufacturers and retailers.

Yet in the past year, consumers likely have become even more dependent on hemp-CBD products because of increased anxiety and stress during the coronavirus pandemic. The widespread economic disruption and uncertainty came at the same time general interest in wellness products was increasing

Because of this and other factors, Nielsen projects that sales will reach $1.7 billion to $2 billion in 2020. The average of that range, $1.85 billion, would represent a 54% increase in year-over-year sales.

Considering that the market could see favorable U.S. Food and Drug Administration guidance or legislation from Congress approving CBD in ingestible products next year, Nielsen expects that by 2025, the market for hemp-derived CBD products will generate $6.9 billion, – a threefold increase over five years.

Sales by category

The availability of different segments of the hemp-CBD market are limited by the types of retailers willing to carry them.

For example, dozens of mainstream retailers have entered the CBD category by picking up topicals such as hand and body creams, balms and cosmetics, although most have been hesitant to sell ingestible products until there is more regulatory clarity from the FDA.

Despite this lack of regulation, ingestibles already are and will continue to be huge moneymakers for manufacturers and retailers. Nielsen estimates that sales for over-the-counter (OTC) supplements will reach more than $588 million in 2020, while other ingestible categories (including beverages, food, candy and gum) will top $400 million.
Inhalable hemp-CBD products are expected to reach $288 million this year.

Comparably, 2025 sales are projected to increase by:

159% for over-the-counter supplements to $1.5 billion.
428% for beverages to $1.2 billion.
197% for inhalables to $792 million.
428% for food items to $595 million.
428% for candy and gum to $373 million.

Manufacturers have been focused on getting CBD approved as a food ingredient — but the food category is one of the smallest CBD segments, according to Nielsen. On the other hand, the prestige category, which includes beauty and skin care products typically available from higher-end retailers, might offer greater opportunity — both in the short term and the future — as sales are expected to increase by nearly 1,000% in the next five years.

Following closely behind food products are the similarly sized hemp-derived CBD beauty products and pet-products segments.

CBD beauty products are projected to reach $191 million in 2020, with estimated 7% growth to $507 million by 2025. Likewise, the hemp-CBD pet products market, estimated at $191 million in sales this year, is projected to grow 7% in five years to $506 million. Like food, however, growth of the pet-products sector is highly dependent on regulatory clarity.

Shore up your plans

Now the industry has a grasp of what increasing use looks like for hemp-CBD sales overall and by category, as well as how certain factors will impact consumer use – and what that means for hemp entrepreneurs and retailers trying to navigate the complex market.

Hemp Industry Daily is pleased to present “How to Navigate the Complicated World of CBD in Retail,” in collaboration with Nielsen Global Connect as part of an ongoing partnership that aims to provide exclusive data on hemp-CBD retail markets and consumer-purchasing behaviors for these products.

In the report, you’ll find data and insights on the existing hemp-CBD consumer product market in the U.S., including:

Estimated sales of hemp-CBD products.
Demographics for current and future CBD consumers.
How and why consumers are using CBD.
Barriers to consumer adoption.
Prices compared to non-CBD products.
Category management trends.
How to stand out at retail.
The federal regulatory outlook.

Source: https://hempindustrydaily.com/exclusive-cbd-demand-could-drive-2020-sales-of-2-billion-with-threefold-growth-projected-by-2025/

Tags: #CanineCBD, #Europe, #Psilocybin, #psychedelic, #Sales, Cannabis, CBD
Posted in All Recent Posts, Thoughtful Brands Inc. | Comments Off on CBD Demand Could Drive 2020 Sales of $2 Billion SPONSOR: Thoughtful Brands International $TBI.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $SHRM.ca $RVV.ca $NOVA.ca

Avicanna $AVCN.ca $AVCNF Reports Third Quarter 2020 Financial Results and Provides Corporate Update $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 9:05 AM on Thursday, November 12th, 2020

http://www.smallcapepicenter.com/Avicana%20square%20logo.jpg

Another double-digit increase in revenue quarter over quarter as the company continues to execute on its business plan to commercialize its brands in different geographic markets and product segments.

Successful launch of the RHO Phyto line of advanced medical cannabis products nationwide in Canada in partnership with Medical Cannabis by Shoppers Drug Mart Inc.

Good Preparation Practices certification and authorization by the National Institute for Drug and Food Surveillance (“INVIMA”) for the sale of compounded pharmaceutical products to service medical prescriptions of individual patients in Colombia.

TORONTO, Nov. 12, 2020 –Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products announces results for the third quarter ended September 30, 2020.

Aras Azadian, Chief Executive Officer of Avicanna, commented “We are thrilled to report the tremendous progress our team continues to make in our commercialization and research efforts. During the third quarter, we were able to demonstrate the superiority of our technologies and products with several strategic commercial partnerships but also with an incredibly successful launch of our medical products in the Canadian market.”

Third Quarter Highlights

The Company continued to make strides in its strategic commercial initiatives, leading to an increase in revenue of approximately 24% from Q2-2020, continuing the trend of double-digit growth, quarter over quarter from Q4-2019. In addition, the Company was able to reach a major milestone with the launch of certain products from its RHO Phyto product line in Canada and further diversified its revenue streams. Below is a summary of the revenue trend over the last four quarters.

Avicanna launched the first product of its RHO Phyto branded line of medical cannabis products on the Medical Cannabis by Shoppers™ (“Shoppers”) platform on August 12, 2020. As of the date of this MD&A, Avicanna has launched its oil drops and sublingual sprays, for a total of four SKUs, through the Shoppers online platform, which offers nationwide service to Canadians.
Certain of the RHO Phyto products are participating in the Medical Cannabis Real-World Evidence study (“MC-RWE study”) at the University Health Network (“UHN”). This first-of-its-kind Canadian study is led by Dr. Hance Clarke, Director of Pain Services at Toronto General Hospital, and will examine the efficacy of a select group of medical cannabis products including Avicanna’s RHO Phyto line of products on patient reported outcomes of pain, sleep and anxiety. This specific study is aligned and in parallel with Avicanna’s comprehensive clinical program of other real-world evidence studies involving the RHO Phyto products and clinical trials on its pharmaceutical pipeline with world-class, Toronto-based medical institutions.
The Company hosted its third annual symposium, “Medical Cannabis 2.0”, through a virtual format on July 21, 2020. The presentations focused on the evolution of medical cannabis including the Avicanna led advancements in R&D for novel cannabinoid delivery forms and formulations. Presenters including Dr. Ruth Ross (Professor and Chair, Department of Pharmacology & Toxicology, Faculty of Medicine, University of Toronto, Senior Scientist, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health) and Dr. Hance Clarke (Staff Anesthesiologist, Director Pain Services, Director Good Hope Ehlers Danlos Clinic, Medical Director of The Pain Research Unit, Department of Anesthesia and Pain Management, Toronto General Hospital, University Health Network, Associate Professor, Department of Anesthesia, University of Toronto). Over 1,000 participants attended the symposium.
The Company announced on September 14, 2020 that through Avicanna LATAM S.A.S., the Company’s pharmacy in Bogota has been certified with Good Preparation Practices and authorized by INVIMA for the sale of compounded pharmaceutical products to service medical prescriptions of individual patients in Colombia. This is the final step in the Company’s fully integrated seed to patient business model in Colombia, which includes cultivation, extraction and manufacturing of pharmaceutical products for the emerging medical market of 50 million people.
Avicanna announced on July 24, 2020 that its research collaborators had received two independent peer-reviewed grants from the Natural Sciences and Engineering Research Council of Canada (“NSERC”). In addition to a recent MITACS award, Dr. Christine Allen, a Professor at the University of Toronto, was awarded an NSERC grant for development of cannabinoid-based pharmaceutical formulations for the treatment of COVID-19 induced lung inflammation. Avicanna further expanded its existing neurobiological research collaboration with Dr. Jibran Khokhar, a Professor at the University of Guelph, with a 2-year NSERC grant to investigate the neural basis of cannabis-induced toxicosis. The NSERC grants are being used to expand the investigators’ collaborative research with Avicanna at little to no additional cost to the Company.
Avicanna and Red White & Bloom Brands Inc. (“RWB”) entered into a distribution agreement (the “Distribution Agreement”) on August 11, 2020, for the exclusive distribution of Avicanna’s hemp-based CBD derma-cosmetic and topical products, branded as Pura H&W™, by RWB in the United States and certain other markets. Under the Distribution Agreement, which has an initial five-year term, RWB will exclusively distribute the Pura H&W™ brand and certain other white label brands at RWB’s direction. In exchange for this exclusivity, RWB is required to pay Avicanna an upfront exclusivity fee in the amount of CAD$250,000 in cash, along with minimum purchase requirements for the rights to be the exclusive distributor of Avicanna’s Pura H&W branded cosmetic products in the US. Under the Distribution Agreement, RWB also has the right to purchase Avicanna’s cosmetic products for distribution into the United States and certain other territories under brands of RWB’s choosing. The initial product offerings under the Distribution Agreement includes body and face lotions, cosmetic creams, gels and serums, as well as soaps and bath bombs.
The Company issued an aggregate of 1,952,410 units (the “August Units”) at a price of $1.40 per August Unit, for aggregate gross proceeds of approximately $2.7 million on August 18, 2020. Each August Unit was comprised of one Common Share and one-half of one Common Share purchase warrant, each whole warrant exercisable into one Common Share at a price of $2.00 per share until August 18, 2022, subject to acceleration rights.
The Company announced on August 24, 2020 that it completed exports of CBG and CBD isolates into the USA and CBD isolate into Germany. The Company also commenced a pilot tracking system for the export of its active pharmaceutical ingredient products in partnership with TruTrace Technologies Inc.
The Company announced on September 4, 2020 that it completed further exports of CBD water soluble formula into the USA and CBD-based cosmetics into the United Kingdom. The Colombian Ministry of Health also granted SMGH a commercial and industrial fabrication quota to produce psychoactive THC derivatives.
The Company announced that it entered into an agreement with a US distributor partner on September 29, 2020, whereby the Company plans to develop certain hemp-derived cannabinoid-based products, including sublingual and sustained release tablets intended for the sleep market for such US distributor. Under the agreement, the Company is developing the intellectual property that forms the basis of the products for a development fee. The Company will receive an ongoing royalty payment based on the gross revenue of the products, and the Company will have the opportunity to supply cannabinoid for the manufacture of the products.
During the quarter, the Company incurred general and administrative (G&A”) expenses that total $2,954,438. While the Company’s G&A expenses did marginally increase from the previous quarter, there were several expenses incurred that were one time in nature. Below is a summary of the adjusted EBITDA of the Company over the last four quarters, indicating its continued improvement.

	Q1 2020	Q2 2020	Q3 2020
Revenue	260,903	709,468	881,956
Adjusted EBITDA*	(3,063,524)	(3,641,496)	(2,608,063)

* Adjusted EBITDA is a Non-GAAP measure. Please refer below for a reconciliation of Net Income (Loss) to EBITDA and Adjusted EBITDA.

Subsequent to quarter end, on November 2, 2020, the Company closed a non-brokered convertible debenture financing, pursuant to which it issued convertible debentures (the “Debentures”) with an aggregate Face Principal Amount (as defined below) of $1,100,000 (the “Debenture Financing”). The Debentures bear interest at 8.0% per annum and will mature on the date that is 12 months from the ‎date of issuance, with the first year of interest payable in advance on the date of ‎issuance and capitalized and added into the principal amount (such aggregate amount being, ‎the “Face Principal Amount”). With these funds the Company was able to strengthen its balance sheet and provide the necessary working capital to make a large commercial push in the first quarter of 2021.

Summary of Operations ($CDN)

	Three Months Ended	Nine Months Ended
	September 30, 2020	September 30, 2019	September 30, 2020	September 30, 2019

			$	$
Revenues	881,956	4,943	1,852,327	45,537
Impairment on inventory	(612,105)	–	(612,105)	–
Inventory Production Costs expensed to Cost of Sales	(439,099)	–	(673,387)	–
Fair value changes in biological assets included in inventory sold	(37,818)	–	(607,370)	–
Unrealized gain/(loss) on changes in fair value of biological assets	(1,103,910)	–	723,361	–
General and administrative	2,954,438	5,673,540	9,064,843	12,604,022
Share-based compensation	839,954	262,498	2,455,916	1,982,066
Depreciation and amortization	419,914	326,983	1,259,742	512,100
Impairment of goodwill	2,520,382	–	3,207,227
Total Expenses	(6,734,688)	(6,263,021)	(15,987,728)	(15,098,188)
Other income (loss)	378,512	72,748	(2,117,968)	473,646
Net loss before taxes	(7,667,152)	(6,185,330)	(17,422,870)	(14,579,005)
Net loss after taxes	(7,667,152)	(6,185,330)	(17,422,870)	(14,579,005)
Weighted average number of Common Shares outstanding – basic and diluted	26,566,915	21,830,153	25,348,330	19,298,899
Loss per share – basic and diluted	(0.35)	(0.33)	(0.82)	(0.84)

Summary of Balance Sheet ($CDN)

	As at September 30, 2020	As at December 31, 2019

Assets	$	$
Cash	101,088	441,757
Amounts receivable	2,442,488	1,202,924
Prepaid assets	652,287	704,632
Biological assets	233,644	117,367
Inventory	2,084,414	1,484,371
Right to use asset	392,516	539,710
Property and equipment	19,951,265	22,622,322
Intangible assets	10,504,182	11,063,900
Derivative asset	1,501,034	3,780,000
Investments	72	72
Goodwill	–	3,207,227
Total Assets	37,862,990	45,164,282
Liabilities and Equity
Amounts payable	4,815,132	5,177,634
Due to related party	4,952,124	3,319,116
Convertible debentures	757,400	715,626
Derivative liability	–	23,434
Lease liability	417,975	555,339
Term loan	–	–
Deferred revenue	3,074,752	3,323,518
Deferred tax liability	2,173,834	2,173,834
Total Liabilities	16,191,217	15,288,501
Shareholder’s equity	21,671,773	29,875,781
Total Liabilities and Shareholder’s Equity	37,862,990	45,164,282

About Avicanna

Avicanna is a diversified and vertically integrated Canadian biopharmaceutical company focused on the research, development and commercialization of plant-derived cannabinoid-based products for the global consumer, medical, and pharmaceutical market segments.

Avicanna is an established leader in cannabinoid research and development, which it primarily conducts at its R&D headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto, Canada and in collaboration with leading Canadian academic and medical institutions. In addition to its developing pharmaceutical pipeline, Avicanna’s team of experts have developed and commercialized several industry leading product lines, including:

Pura H&W: an advanced and clinically tested line of CBD consumer dermacosmetic products; and,
RHO Phyto: an advanced line of medical cannabis products containing varying ratios of CBD and THC currently available nation-wide across Canada in partnership with Medical Cannabis by Shoppers™, a subsidiary of Shoppers Drug Mart. RHO Phyto is the first strictly medical formulary of advanced “Cannabis 2.0” products, containing oils, sprays, capsules, creams, and gels, all developed with scientific rigour, manufactured under GMP standards and supported by pre-clinical data.

With ongoing clinical trials on its dermacosmetic (Pura H&W), medical cannabis (RHO Phyto) and a pipeline of pharmaceutical products, Avicanna’s dedication to researching the important role that cannabinoids play in an increasingly wider scope of products has been at the core of the Company’s vision since its inception. Furthermore, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.

Avicanna manages its own supply chain including cultivation and extraction through its two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa Marta, Colombia. Through these sustainable, economical, and industrial scale subsidiaries, Avicanna cultivates, processes, and commercializes a range of cannabis and hemp cultivars dominant in CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by completing the first ever export of hemp seeds from Colombia.

SOURCE Avicanna Inc.

Stay Connected

For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email at [email protected].

Cautionary Note Regarding Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation (each such statement a “forward-looking statement”). Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Avicanna’s current beliefs and assumptions regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Avicanna’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, the Company’s revenues to continue to increase through fiscal 2021, the Company’s anticipated activities and results of its various commercial initiatives, its availability and sufficiency of working capital, the anticipated growth of the Company’s business in the first quarter of 2021 and the anticipated further development and improvement of products by the Company.

By identifying such information and statements in this manner, Avicanna is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Avicanna to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking statements contained in this press release, Avicanna has made certain assumptions.

Among others, the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: decreases in the prevailing prices for cannabis and cannabis products in the markets in which the Company operates; adverse changes in applicable laws; adverse changes in the application or enforcement of current laws, including those related to taxation; increasing costs of compliance with extensive government regulation; changes in general economic, business and political conditions, including changes in the financial markets ; risks related to licensing, including the ability to obtain the requisite licenses or renew existing licenses for the Company’s existing and proposed operations; dependence upon third party service providers, skilled labor and other key inputs; risks inherent in the agricultural and retail business; intellectual property risks; risks related to litigation; dependence upon senior management; and the other risks disclosed in the Company’s long form final prospectus dated July 8, 2019 and the Company’s annual information form dated April 15, 2020. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Avicanna believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking statements are reasonable, undue reliance should not be placed on such statements, and no assurance or guarantee can be given that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Tags: cannabinoids, Cannabis, Canopy Growth, CBD, CSE, Harvest Health, Hexo Corp, Marijuana, Medical Cannabis by Shoppers, Rho Phyto, Tilray
Posted in All Recent Posts, Avicanna Inc. | Comments Off on Avicanna $AVCN.ca $AVCNF Reports Third Quarter 2020 Financial Results and Provides Corporate Update $WEED.ca $TLRY $HARV.ca

TransCanna $TCAN.ca Announces Five Year Deal with Fresca LLC $VFF.ca $ACB.ca $CGC.ca $GTII.ca $TEQ.ca

Posted by AGORACOM-JC at 7:26 AM on Thursday, November 12th, 2020

Lyfted Farms has entered into a 5-year agreement with Fresca LLC to promote and co-brand premium indoor cannabis flower
The resulting new retail SKU’s have surpassed several prior sales velocity records for Lyfted Farms
Sales velocity has long been a key indicator for demand and viable results demonstrating the products are well positioned

Vancouver, British Columbia–(November 12, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (GSE: TH8) (“TransCanna” or the “Company”) announces the collaboration of Lyfted Farms with Fresca LLC; breaks sales velocity records.

Lyfted Farms has entered into a 5-year agreement with Fresca LLC to promote and co-brand premium indoor cannabis flower. The resulting new retail SKU’s have surpassed several prior sales velocity records for Lyfted Farms. Sales velocity has long been a key indicator for demand and viable results demonstrating the products are well positioned.

This collaboration highlights the marketplace power of California’s most authentic indoor cultivator combined with the Fresca Brand and distribution channels into the world-famous Cookie’s, Lemonade, and Dr. Greenthumb stores.

Bob Blink, founder of Lyfted Farms and CEO of TransCanna, shares that, “The opportunity to bring Lyfted Farms reputation for consistently high quality indoor cannabis flower into the Fresca Brand and the Cookie’s retail distribution system is exciting and will enable us to showcase the production capacity of the Daly Facility.”

Gilbert Milam Jr., aka “Berner” @berner415, Founder and CEO of Cookie’s, notes “The owners of Fresca helped innovate Bay Area culture when I was growing up through music…when they mentioned to me about starting a cannabis brand…I recommended that they find a quality indoor cultivator and I think Lyfted Farms is the perfect partner for them. We look forward to carrying their brand onto our shelves and watching their Statewide expansion.”

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed, Company building cannabis-focused brands for the California lifestyle through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors
Bob Blink, CEO
604-349-3011

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.

The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including that operations will commence at the Company’s Daly facility in Modesto, California, as and when expected.

These forward-looking statements involve numerous known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially from any future results, events or developments expressed or implied by such forward-looking statements. Risks and uncertainties associated with the forward-looking information in this news release include, among others, dependence on obtaining and maintaining regulatory approvals, including state, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits to complete upgrades to its Daly facility in a timely manner; engaging in activities which currently are illegal under U.S. federal law and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including U.S. state-law legalization, particularly in California, due to inconsistent public opinion, perception of the medical-use and adult-use marijuana industry, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth;; reliance on management; and the effect of capital market conditions and other factors (including those related to the COVID-19 pandemic) on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look, except in accordance with applicable securities laws.

Tags: Aphria Inc, Aurora Cannabis Inc, california cannabis, Cannabis, Canopy Growth Corp, CBD, Cronos Group Inc, CSE, Hemp, Marijuana
Posted in All Recent Posts, Featured, TransCanna Holdings Inc. | Comments Off on TransCanna $TCAN.ca Announces Five Year Deal with Fresca LLC $VFF.ca $ACB.ca $CGC.ca $GTII.ca $TEQ.ca

Hollister Biosciences $HOLL.ca $HSTRF Launches Direct to Consumer Cannabis Delivery Platform, Dreamy Delivery $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 8:15 AM on Tuesday, November 10th, 2020

https://prnewswire2-a.akamaihd.net/p/1893751/sp/189375100/thumbnail/entry_id/1_dd2snc3b/def_height/400/def_width/400/version/100011/type/1

Announced the launch of its direct to consumer cannabis delivery platform, Dreamy Delivery
Company soft launched Dreamy Delivery to friends and family in the San Francisco Bay Area of Northern California, to ensure a seamless customer experience in early Q4 of 2020
Company hopes to launch Dreamy in Sacramento and the Central Coast of California by late Q4 of 2020 with the ultimate goal of delivering Cannabis statewide

VANCOUVER, BC , Nov. 10, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co. ” or ” Hollister “) a diversified cannabis branding company with products in over 280 dispensaries throughout California , and over 80 dispensaries throughout Arizona , is pleased to announce the launch of its direct to consumer cannabis delivery platform, Dreamy Delivery (” Dreamy ” or the ” Platform “).

The company soft launched Dreamy Delivery to friends and family in the San Francisco Bay Area of Northern California ( “Bay Area “), to ensure a seamless customer experience in early Q4 of 2020. The Company has expanded the Platform, with Dreamy now successfully delivering to legal cannabis consumers in the Bay Area. The Company hopes to launch Dreamy in Sacramento and the Central Coast of California by late Q4 of 2020 with the ultimate goal of delivering Cannabis statewide.

Carl Saling , CEO of Hollister , shared: “This is a major first step in our quest to be the dominant direct to consumer platform delivering cannabis to the entire state of California .”

Website: www.dreamydelivery.com

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products. Our wholly owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed “forward-looking statements”. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com .

Tags: Aphria Inc, Arizona, Aurora Cannabis Inc, california cannabis, Cannabis, Canopy Growth Corp, CBD, Cronos Group Inc, CSE, Fire & Flower Holdings Corp, hash, Hemp, Proposition 207, small cap
Posted in Featured, Hollister Biosciences | Comments Off on Hollister Biosciences $HOLL.ca $HSTRF Launches Direct to Consumer Cannabis Delivery Platform, Dreamy Delivery $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

VIDEO – Hollister $HOLL.ca $HSTRF Reports Record Q3 Revenues With $12.5M From 360+ Dispensaries In California and Arizona $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 4:23 PM on Monday, November 9th, 2020

Hollister Biosciences (HOLL:CSE) is a multi-state operator with multiple, high-quality products that are now carried in 280 of California’s 600 dispensaries, where it also claims California’s #1 hash infused pre-roll “HashBone” … and if that is all they had you would have the makings of a great small cap cannabis company.

But there is more …. way more.

Venom Extracts is their 100% owned subsidiary that is absolutely dominating the state of Arizona. More than just lip service:

Venom just surpassed $30,000,000 (MILLION) in revenue YEAR TO DATE
Venom Extracts is one of Arizona’s premier extract brands
One of the state’s largest producers of medical cannabis distillate and related products
The products are award winning
….. And it is run by the absolute coolest guy in small cap Cannabis – Jake Cohen

THE NUMBERS SAY IT ALL

1. RECORD Q3 REVENUE $12.5M

2. CRAZY REVENUE GROWTH 5,200%

3. RECORD EBITDA $1.265M (vs a loss of $362,000) In case you’re wondering if this was a fluke quarter, this is what Q2 looked like:

RECORD REVENUE of $US 8.47M, compared to $200,000 last year and representing an increase of 4,170%
NET INCOME of $300,000, compared to a loss of $2.1M, representing a turnaround of $2.4M over last year

HOLLISTER HEADED TOWARDS $50,000,000 REVENUE?

If you’re paying attention, HOLL is achieving enormous growth both year over year and sequentially. If we extrapolate the latest Q3 numbers, Hollister is on a $50,000,000 annualized revenue run rate assuming no further growth.

But there is more.

The State of Arizona just approved recreational cannabis in Arizona. This is a potential windfall for Venom given the fact its brand, reputation and dispensary penetration from its award winning medical cannabis is about as good as it gets. How good is Hollister now?

How good does it get?

Watch this incredible interview with Venom Extracts Founder Jake Cohen, the coolest exec in small cap cannabis because he delivers incredible results with sweat, swagger and great swag to boot.

Watch this interview or listen by Podcast on Apple, Google, Spotify or your favourite podcaster.

Tags: Aphria Inc, Arizona, Aurora Cannabis Inc, california cannabis, Cannabis, Canopy Growth Corp, CBD, Cronos Group Inc, CSE, Fire & Flower Holdings Corp, hash, Hemp, Proposition 207, small cap
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, Hollister Biosciences | Comments Off on VIDEO – Hollister $HOLL.ca $HSTRF Reports Record Q3 Revenues With $12.5M From 360+ Dispensaries In California and Arizona $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Harborside Inc. $HBOR Announces Cultivation Facility Upgrades and Launch of Clones Sales at All Harborside Retail Stores $VFF.to $HARV.ca $ACB.to

Posted by AGORACOM at 8:28 AM on Friday, November 6th, 2020

OAKLAND, Calif. and TORONTO, Nov. 6, 2020 /CNW/ – Harborside Inc. (“Harborside”, or the “Company”) (CSE: HBOR), (OTCQX: HBORF), a California-focused, vertically-integrated cannabis enterprise, announced today that it is engaging in a substantial upgrade of one of its approximately 45,000 square foot greenhouses at its 47-acre integrated production campus in Salinas, California (the “Salinas Facility”).

The planned upgrades include, among other things, the installation of blackout curtains and supplemental LED grow lights in the greenhouse. Following the successful completion of these upgrades, on an annualized basis. the Company expects an approximately 50% increase in production from this greenhouse, an expected approximately 10% increase in bulk wholesale revenue capacity, and an approximately 7% increase in the total productive capacity of the Salinas Facility. The project is expected to be completed within the first quarter of 2021 and the Company expects that the total cost of the updates will be fully recouped within the first twelve months of operation following completion of the project.

In addition, the Company announced today that its in-house brand, Harborside Farms, a highly recognized, customer-centric product line, will commence sales of clones grown at its Salinas Facility at all Harborside branded locations, including Desert Hot Springs. On a year-over-year basis, sales of Harborside Farms products have grown by 229% at Harborside’s iconic dispensaries capturing 42% of its total retail flower sales through the end of the third quarter of 2020, demonstrating continuing strength and customer loyalty to one of its flagship brands.

“We have carved out a strong reputation for supplying high-quality cannabis products to the growing California market and these upgrades are a crucial investment that will fuel our growth heading into 2021,” said Peter Bilodeau, Interim CEO and Chairman of Harborside. “Leveraging the strength of our Salinas facility, we’re thrilled to be officially commencing sales of clones that are grown at our farm and only available at our stores immediately. This new in-house product category was developed utilizing sustainable cultivation techniques to provide discerning consumers with access to locally grown, high-quality cannabis.”

The Company’s clone initiative aims to capitalize on these trends and the continued high-quality production from its Salinas Facility, and will underscore the single-source, local nature of the Harborside Farms brand, as well as its emphasis on sustainable cultivation practices. The initiative will also continue to enhance the Company’s retail gross margins by adding an additional in-house product category sourced internally from its Salinas Facility.

At its retail dispensaries, clones (inclusive of seeds and seedlings) are expected to comprise approximately 5% of the Company’s total annual retail sales, or approximately $2M in annual net retail revenue in 2020. The Company’s average gross margin in this category is approximately 52% through the end of the third quarter. The Company anticipates Harborside Farms clones capturing at least 50% of total clone sales throughout the course of 2021, resulting in total sales of approximately $1M, with estimated gross margins as high as 90%. The Company expects average gross margins across its entire clones category to increase to approximately 70% during 2021 as a result of this initiative, providing an approximate 18% improvement over its expected annual average gross margin in this category as compared to 2020.

For the latest news, activities, and media coverage, please visit the Harborside corporate website at http://www.investharborside.com or connect with us on LinkedIn, Facebook, and Twitter.

About Harborside:
Harborside Inc. is one of the oldest and most respected cannabis retailers in California, operating three of the major dispensaries in the San Francisco Bay Area, a dispensary in the Palm Springs area outfitted with Southern California’s only cannabis drive-thru window, a dispensary in Oregon and a cultivation/production facility in Salinas, California. Harborside has played an instrumental role in making cannabis safe and accessible to a broad and diverse community of California consumers. Co-founded by Steve DeAngelo and dress wedding in 2006, Harborside was awarded one of the first six medical cannabis licenses granted in the United States and today holds cannabis licenses for retail, distribution, cultivation, nursery and manufacturing. Harborside is currently a publicly listed company on the CSE trading under the ticker symbol “HBOR”. Additional information regarding Harborside is available under Harborside’s SEDAR profile at www.sedar.com.

Tags: california cannabis, Cannabis, Canopy Growth Corp, CSE, Greenhouse, Hemp, small cap, tsx, Wholesale
Posted in All Recent Posts, Harborside | Comments Off on Harborside Inc. $HBOR Announces Cultivation Facility Upgrades and Launch of Clones Sales at All Harborside Retail Stores $VFF.to $HARV.ca $ACB.to

Hollister $HOLL.ca $HSTRF Provides Comment on Approval of Recreational Cannabis in Arizona $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 10:58 PM on Wednesday, November 4th, 2020

Company comments on the successful passage of Proposition 207 – legalizing the cultivation, sale and consumption of recreational cannabis in the state of Arizona
“Seeing recreational Cannabis legalized in the state is an encouraging sign and is hopefully another step toward federal legalization. It should lead to increased tax revenue and job creation. The recreational cannabis market in Arizona could be valued at up to US $760 million by 2024…” Shared Jacob Cohen , Founder of Venom Extracts, Hollister’s 100% owned subsidiary based in Arizona .

VANCOUVER, BC , Nov. 4, 2020 – Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the ” Company “, ” Hollister Cannabis Co. ” or ” Hollister “) a diversified cannabis branding company with products in over 280 dispensaries throughout California , and over 80 dispensaries throughout Arizona provides comment on the successful passage of Proposition 207 – legalizing the cultivation, sale and consumption of recreational cannabis in the state of Arizona .

“Seeing recreational Cannabis legalized in the state is an encouraging sign and is hopefully another step toward federal legalization. It should lead to increased tax revenue and job creation. The recreational cannabis market in Arizona could be valued at up to US $760 million by 2024 1 , significantly expanding the total addressable market for Cannabis in the state. We look forward to making our product line available to both the medical and recreational end user.” Shared Jacob Cohen , Founder of Venom Extracts, Hollister’s 100% owned subsidiary based in Arizona .

Arizona Presence

Hollister , through its 100% owned subsidiary, Venom Extracts (” Venom “), is one of Arizona’spremier extract brands and one of the state’s largest producers of award-winning medical cannabis distillate and related products. With an experienced management team and unparalleled reputation for quality, Venom prides itself as a differentiated extraction company by producing legal cannabis products at a price point that allows retailers to generate higher profits. Focused on proprietary efficiencies, Venom is able to produce more product per square foot than its competition, maintaining lower costs and risks than a typical extraction company.

Website: www.venomextracts.com

About Hollister Biosciences Inc.

Website : www.hollistercannabisco.com

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

1 Source: Marijuana Business Daily

View original content to download multimedia: http://www.prnewswire.com/news-releases/hollister-provides-comment-on-approval-of-recreational-cannabis-in-arizona-301166780.html

SOURCE Hollister Biosciences Inc.

Tags: Aphria Inc, Arizona, Aurora Cannabis Inc, california cannabis, Cannabis, Canopy Growth Corp, CBD, Cronos Group Inc, CSE, Fire & Flower Holdings Corp, hash, Hemp, Proposition 207, small cap, tsx
Posted in All Recent Posts, Hollister Biosciences | Comments Off on Hollister $HOLL.ca $HSTRF Provides Comment on Approval of Recreational Cannabis in Arizona $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Arizona Voters Approve #Marijuana Legalization Ballot Measure SPONSOR: Hollister Biosciences $HOLL.ca $HSTRF $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM-JC at 2:15 PM on Wednesday, November 4th, 2020

SPONSOR: Hollister Biosciences Inc. (HOLL:CSE) A vertically integrated Cannabis company with products in 280 California dispensaries, over 80 dispensaries throughout Arizona, joint ventures, licensing agreements and partnerships with Global brands. For the period beginning July 1 ^st , 2020 and ending September 30 ^th , 2020, Hollister generated record quarterly revenue of CDN$ 12.5 million and CDN$ 1.265 million in EBITDA. Learn More.

Arizona Voters Approve Marijuana Legalization Ballot Measure

A measure to legalize marijuana has been approved by Arizona voters, according to a projection by the Associated Press.
Advocates have paid close attention to the ballot initiative, as the state’s voters rejected a prior legal cannabis proposal in 2016.
Under the new legalization law, adults will be able to possess up to an ounce of marijuana at a time and cultivate up to six plants for personal use.

By Kyle Jaeger

AZ Proposition 207: Legalize Marijuana

Candidate	Votes	Percent
Yes done	1,596,548	59.85%
No	1,071,255	40.15%

2,667,803 votes counted. 81.64% – 98.11% in.

Results tracker sponsored by ETFMG | MJ.

“Until now, Arizona had imposed some of the strictest prohibition laws in the country; in some instances, the possession of even small amounts of marijuana was classified as a felony,” NORML Executive Director Erik Altieri said. “By rejecting this failed policy, no Arizonan going forward will be saddled with a criminal conviction for engaging in the personal possession or cultivation of cannabis, or face the lifelong stigma that comes with it.”

“Proposition 207 will disrupt the illicit market, end low-level marijuana arrests, create jobs and new revenue,” he added. “This result once again shows that marijuana legalization is not exclusively a ‘blue’ state issue, but an issue that is supported by a majority of all Americans—regardless of party politics.”

Polling was mixed heading into Election Day, with surveys consistently showing the proposal ahead, though by differing margins. In September, the Smart and Safe Arizona campaign shared an internal poll with Marijuana Moment that showed 57 percent of likely voters supported the initiative, but a separate survey found just 46 percent in favor of the policy change. Additional polls last month showed the cannabis measure with a significant and growing lead.

The measure also contains several restorative justice provisions such as allowing individuals with prior marijuana convictions to petition the courts for expungements and establishing a social equity ownership program.

Cannabis sales will be taxed at 16 percent. Tax revenue will cover implementation costs and then be divided among funds for community colleges, infrastructure, a justice reinvestment and public services such as police and firefighters.

The Department of Health Services will be responsible for regulating the program and issuing cannabis business licenses. It will also be tasked with deciding on whether to expand the program to allow for delivery services.

The law technically goes into effect upon passage and after the voters are certified, which is expected to take place on November 30. After that point adults could legally use, possess and cultivate cannabis. However, regulators will still have to promulgate rules for overseeing the commercial industry. They can issue licenses starting in January 2021, and the first shops could be approved by February 1.

“Just four years after legalization was narrowly defeated, voters in Arizona turned out to send a clear message that they support marijuana legalization,” Steve Hawkins, executive director of the Marijuana Policy Project, said. “Following this victory, adults will no longer be treated as criminals for using a substance that is safer than alcohol and will be able to access it from safe and regulated businesses.”

Like other drug policy reform campaigns throughout the U.S., Smart and Safe Arizona faced significant obstacles qualifying its measure for the ballot amid the coronavirus pandemic.

At one point, activists asked the state Supreme Court to allow them to collect signatures electronically amid social distancing mandates, but that request was rejected.

Ultimately, the campaign submitted about 420,000 raw signatures. Secretary of State Katie Hobbs said that her office verified the petitions and determined that approximately 255,080 valid signatures were turned in. At least 237,645 were needed to qualify.

Opponents of the proposal, including Gov. Doug Ducey (R), released official voter guide arguments against the initiative in August. Supporters filed arguments as well, and all were circulated to voters in a pamphlet printed by the state.

Prohibitionists also released a series of attack ads that including misleading claims about what the measure would do and what has occurred in states that have already enacted cannabis legalization.

Source: https://www.marijuanamoment.net/arizona-voters-approve-marijuana-legalization-ballot-measure/

Tags: Aphria Inc, Aurora Cannabis Inc, california cannabis, Cannabis, Canopy Growth Corp, CBD, Cronos Group Inc, CSE, Fire & Flower Holdings Corp, Green Thumb Industries, hash, Hemp, Indus Holdings Inc., small cap, tsx
Posted in All Recent Posts, Hollister Biosciences | Comments Off on Arizona Voters Approve #Marijuana Legalization Ballot Measure SPONSOR: Hollister Biosciences $HOLL.ca $HSTRF $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

TransCanna $TCAN.ca Provides Corporate Update – Production Capacity of Lyfted Farms Facility is Currently Sold-Out Until March, 2021 $VFF.ca $ACB.ca $CGC.ca $GTII.ca $TEQ.ca

Posted by AGORACOM-JC at 10:22 AM on Monday, November 2nd, 2020

Final license achieved July 2020
16,000 sq ft Distribution Space open for business in Q4
Contracts in place with much larger farms than the Company were able to service out of the smaller facility (16,000sq ft vs. 1,250 sq ft)
Build-out for cultivation has begun
The first harvest from cultivation in Daly expected in Q1
“Phase 1” Daly canopy sq. ft. capable of generating $30M + USD/year in cultivation revenue alone
In combination with increased Distribution capacity on track for 2021 rev target of $60M+ out of this facility

Vancouver, British Columbia–(November 2, 2020) – TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is very pleased to provide a corporate update:

Lyfted Farms Products are in High Demand and Selling Out
Lyfted Farms Secures Multiple Off-Take Agreements
Q4 Revenue Guidance
Crop Management Business Launched
Daly Facility Update

Product Update

Lyfted Farms flower is one of a very few branded indoor cultivation companies that routinely delivers on customer expectations for quality. This is reflected in the caliber of the retail stores that carry Lyfted Farms and by customer demand for our products. Lyfted Farms genetic library is fully capable of delivering new strains seasonally and has evolved into a trend-defining marketplace leader where other cannabis entities watch and emulate our products. Material process improvements have resulted in larger “nugget” sizing, increased THC levels, and a more robust curing cycle yielding better taste and aromatic profiles. These changes have had a positive effect on the pricing structure, with a 66% increase in wholesale pricing and a 100% increase in gross margins.

Off-Take Agreements

The Company has secured multiple off-take agreements in anticipation of late Q1 production coming out of the Daly facility. Shareholders will be given greater detail in subsequent news releases when all material details are finalized. As a result of the status of these agreements, the Company has tremendous confidence it will achieve or exceed its stated 2021 revenue targets.

Contracts with the likes of renowned retail partner Cookies, where Lyfted Farms currently has five sku’s in stores, provides the additional benefit of cost savings by not requiring a large in-house sales team or paying expensive 3rd party commissions, which are common in the Cannabis Sector.

Revenue Guidance

Lyfted Farms products produced out of the Company’s smaller Lyfted Farms facility continue to sell out and exceed sales expectations. Due to the increased capacity of the first 16,000 sq ft of distribution space in the Daly facility, the Company anticipates its Fourth Quarter to be its strongest of the year. The Company’s internal gross revenue target for the 2020 fiscal year ranges from CAD$12,000,000 up to CAD$14,000,000 (with anticipated net profits from sales of $600,000 up to $700,000). The Company is on track to achieve this benchmark.

With the opening of the Daly facility, associated off-take agreements, high demand for sales, and a strong distribution division, the Company maintains its guidance for a gross revenue target of CAD$55,000,000 to CAD$75,000,000 (with anticipated net profits from sales of $6,600,000 up to $9,000,000) for the fiscal year 2021. This revenue guidance is only for phase one of four in the Daly facility with phase one construction costs estimated to be CAD$3,172,500.

“With a significant portion of the year spent on submitting and obtaining licenses, we expect investor attention to shift to our 2021 performance. Our goal has always been to drive shareholder value through incremental sales contracts and quality products. This focus has us well-positioned to begin the build-out of the Daly building and scale our business,” States Bob Blink, company CEO. “I am very proud of how the team has come together through unprecedented events both globally and in our own back yard. 2021 will be a very exciting year for the Company.”

Crop Management Services Division

On October 8, 2020, the Company announced Lyfted Farms’ crop services management division (LFCSMD) first facility would come online January 1, 2021. This initiative is on schedule and will begin generating an additional revenue stream for the Company over and above the already thriving cultivation and distribution divisions. The first payments to LFCSMD are set to commence December 1, 2020. LFCSMD allows the Company to further monetize its genetic catalogue and further the Company’s reputation within the industry as best in class cultivators and operators. Additionally, this allows the Company to build out its supply chain — feeding its growing fulfillment and white-labeling business and maximizing efficiencies within the Daly Facility.

Daly Facility Update

The licensing and engineered build-out of the Daly Facility continues to be the core strength for the company. The amalgamation of a number of California’s strongest cannabis brands coming into the largest and most efficient facilities in the State is a truly powerful combination.

Updates at a glance:

Final license achieved July 2020
16,000 sq ft Distribution Space open for business in Q4
- contracts in place with much larger farms than the Company were able to service out of the smaller facility (16,000sq ft vs. 1,250 sq ft)
Build-out for cultivation has begun
The first harvest from cultivation in Daly expected in Q1
“Phase 1” Daly canopy sq. ft. capable of generating $30M + USD/year in cultivation revenue alone
In combination with increased Distribution capacity on track for 2021 rev target of $60M+ out of this facility

Other Highlights

Smaller Lyfted Farms Facility has outperformed expectations.

Production capacity of Lyfted Farms facility is currently sold-out until March, 2021
Average sales price per gram has increased from $5.70/gram to $8.57/gram, or +66% (increased demand and collaboration/co-branding) & 100% increase in gross margin
Average total harvest weight per room is trending up

Summary

Company performance and development of our team and human capital has been extraordinary. With the current global pandemic and wildfires in California, the Company has experienced many challenges over the past six months. The dedication and commitment by team members have given TransCanna stability and galvanized the opportunity for significant growth in the near term.

About TransCanna Holdings Inc.

TransCanna Holdings Inc. is a California based, Canadian listed Company building cannabis-focused brands for the California lifestyle through its wholly-owned California subsidiaries.

For further information, please visit the Company’s website at www.transcanna.com or email the Company at [email protected].

On behalf of the Board of Directors
Bob Blink, CEO
604-349-3011

Forward-Looking Statements

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs regarding future events of management of the Company. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. This information and these statements, referred to herein as “forward-looking statements”, are not historical facts, are made as of the date of this news release and include without limitation estimates and forecasts and statements as to management’s expectations for growth and the commencement of operations of the Company’s Daly facility.

Tags: Aphria Inc, Aurora Cannabis Inc, california cannabis, Cannabis, Canopy Growth Corp, CBD, Cronos Group Inc, CSE, Hemp, Marijuana, OrganiGram Holdings Inc
Posted in All Recent Posts, Featured, TransCanna Holdings Inc. | Comments Off on TransCanna $TCAN.ca Provides Corporate Update – Production Capacity of Lyfted Farms Facility is Currently Sold-Out Until March, 2021 $VFF.ca $ACB.ca $CGC.ca $GTII.ca $TEQ.ca

CLIENT FEATURE: Avicanna $AVCN.ca $AVCNF Delivering The Vertically Integrated #Cannabis Company That Others Failed To $WEED.ca $TLRY $HARV.ca

Posted by AGORACOM-JC at 5:54 PM on Wednesday, October 28th, 2020

Avicanna (AVCN :TSX) (AVCN : OTCQX) ( 0NN: FSE) is a vertically-integrated biopharmaceutical company developing and commercializing various cannabinoid-based products for the global marketplace.

When we say vertically integrated, we mean it. Avicanna has 4 fully operating divisions to address the entire market for Cannabis products as follows:

1. The company has a full line of high end CBD based skin care products serving the consumer retail segment with Canadian distribution through Medical Cannabis by Shoppers, as well as global distribution later this year.

2. Avicanna’s superior medical cannabis line also features products distributed through Medical Cannabis by Shoppers, the online arm of Canada’s largest drugstore chain. In addition, the company recently received certification and authorization for the sale of pharmaceutical cannabinoid products with medical prescriptions in Colombia.

3. Avicanna also hosts a full pipeline of Pharmaceuticals in various stages of trials to address Dermatology, Psychiatry, Neurology, Pain and Oncology. Three of the company’s products are already as far as phase 2.

AND… if that is not enough …

4. Avicanna’s Colombian cultivation division hosts 500,000 Sq ft of low cost and USDA certified organic Cannabis Cultivation. The company recently Made History As The First Ever Export Of Feminized Hemp Seeds From Colombia To The United States. 7,000,000 Seeds For $380,000, with an additional 75,000,000 Seeds Available For Export In Several Pending Transactions.

Hub On AGORACOM / Corporate Profile

Tags: cannabinoids, Cannabis, Canopy Growth, CBD, CSE, Harvest Health, Hexo Corp, Marijuana, Medical Cannabis by Shoppers, Rho Phyto, Tilray, tsx
Posted in AGORACOM Client Feature, All Recent Posts, Avicanna Inc. | Comments Off on CLIENT FEATURE: Avicanna $AVCN.ca $AVCNF Delivering The Vertically Integrated #Cannabis Company That Others Failed To $WEED.ca $TLRY $HARV.ca

Posts Tagged ‘Cannabis’

Arizona Voters Approve Marijuana Legalization Ballot Measure

AZ Proposition 207: Legalize Marijuana

Categories